Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment


B. Spivak, M.D., Gehah Psychiatric Hospital, Beilinson Medical Center, Petah Tiqva 49 100, Israel


Development of neuroleptic malignant syndrome (NMS) following discontinuation of high-dose and high-potency neuroleptic agents is described. This case, although rare and atypical, should alert clinicians to consider the possibility of NMS as a complication of abrupt neuroleptic drug withdrawal. It is suggested that dopaminergic imbalance, as opposed to excessive dopaminergic blockade, may also play a role in the precipitation of NMS.